Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Anplag vs Brilinta in Healthy Pakistani Men
NCT04941196Phase 1Completed
- Sponsor
- University of Karachi
- Start
- Oct 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ticagrelor in acute coronary syndrome (ACS) and myocardial infarction (MI) (2 arms), sponsored by University of Karachi. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 1 more. Started Oct 2020; status: completed.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)
Beyond the preview
Go deeper on NCT04941196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941196.